dc.contributor.author | Briassoulis, E. Ch | en |
dc.contributor.author | Agnantis, Niki J. | en |
dc.contributor.author | Zagorianakou, P. | en |
dc.contributor.author | Kamina, S. | en |
dc.contributor.author | Gorezi, M. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Bai, M. C. | en |
dc.creator | Briassoulis, E. Ch | en |
dc.creator | Agnantis, Niki J. | en |
dc.creator | Zagorianakou, P. | en |
dc.creator | Kamina, S. | en |
dc.creator | Gorezi, M. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Bai, M. C. | en |
dc.date.accessioned | 2018-06-22T09:52:42Z | |
dc.date.available | 2018-06-22T09:52:42Z | |
dc.date.issued | 2001 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41462 | |
dc.description.abstract | The clinical relevance of quantitative assessment of tumor-tissue expression of the bcl-2 protein in operated stage II breast cancer was investigated in this study. Thirty-five cases were studied by immunohistochemistry for the expression of bcl-2 protein and analyzed for disease outcome. One fourth (25%) of the cases were negative and 57% demonstrated near-absolute expression of the bcl-2 protein. No association was found between immunohistochemical detection of the protein with age, hormonal receptor status and tumor grading other than between bcl-2 and estrogen receptor expression (p=0.01). An impressively positive impact of near-absolute expression of bcl-2 on clinical outcome was identified. Our results provide evidence that quantitative assessment of bcl-2 expression constitutes a new approach in early breast cancer With potential clinical implications. We consider that molecular sub-staging of patients with stage II breast cancer by level of bcl-2 expression provides additional important prognostic information and prompts for investigation of its clinical significance on the issue of adjuvant systemic therapy. | en |
dc.language.iso | eng | en |
dc.source | Journal of Experimental and Clinical Cancer Research | en |
dc.subject | Age | en |
dc.subject | Article | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Breast cancer | en |
dc.subject | Breast neoplasms | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Chemotherapy | en |
dc.subject | Neoplasm staging | en |
dc.subject | Predictive value of tests | en |
dc.subject | Priority journal | en |
dc.subject | Retrospective studies | en |
dc.subject | Disease-free survival | en |
dc.subject | Treatment outcome | en |
dc.subject | Prognosis | en |
dc.subject | Cancer staging | en |
dc.subject | Time factors | en |
dc.subject | Survival rate | en |
dc.subject | Adjuvant | en |
dc.subject | Bcl-2 | en |
dc.subject | Protein bcl 2 | en |
dc.subject | Protein expression | en |
dc.subject | Immunohistochemistry | en |
dc.subject | Estrogen receptor | en |
dc.subject | Breast-cancer | en |
dc.subject | Diagnostic value | en |
dc.subject | Outcomes research | en |
dc.subject | Proto-oncogene proteins c-bcl-2 | en |
dc.subject | Quantitative assay | en |
dc.title | Near-absolute expression of the bcl-2 protein identifies a subgroup of stage II breast cancer patients with a most favorable outcome. Results of a clinicopathological study | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 20 | |
dc.description.issue | 3 | |
dc.description.startingpage | 341 | |
dc.description.endingpage | 344 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |